Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy

Overview

Journal Hum Gene Ther

Specialties Genetics
Pharmacology

Date 2017 Jul 15

PMID 28707952

Citations 31

Authors

Rachael A Potter

Danielle A Griffin

Patricia C Sondergaard

Ryan W Johnson

Eric R Pozsgai

Kristin N Heller

Ellyn L Peterson

Kimmo K Lehtimaki

Hillarie P Windish

Plavi J Mittal

Douglas E Albrecht

Jerry R Mendell

Louise R Rodino-Klapac

Affiliations

Soon will be listed here.

Abstract

Dysferlinopathies comprise a family of disorders caused by mutations in the dysferlin (DYSF) gene, leading to a progressive dystrophy characterized by chronic muscle fiber loss, fat replacement, and fibrosis. To correct the underlying histopathology and function, expression of full-length DYSF is required. Dual adeno-associated virus vectors have been developed, defined by a region of homology, to serve as a substrate for reconstitution of the full 6.5 kb dysferlin cDNA. Previous work studied the efficacy of this treatment through intramuscular and regional delivery routes. To maximize clinical efficacy, dysferlin-deficient mice were treated systemically to target all muscles through the vasculature for efficacy and safety studies. Mice were evaluated at multiple time points between 4 and 13 months post treatment for dysferlin expression and functional improvement using magnetic resonance imaging and magnetic resonance spectroscopy and membrane repair. A systemic dose of 6 × 10 vector genomes resulted in widespread gene expression in the muscles. Treated muscles showed a significant decrease in central nucleation, collagen deposition, and improvement of membrane repair to wild-type levels. Treated gluteus muscles were significantly improved compared to placebo-treated muscles and were equivalent to wild type in volume, intra- and extramyocellular lipid accumulation, and fat percentage using magnetic resonance imaging and magnetic resonance spectroscopy. Dual-vector treatment allows for production of full-length functional dysferlin with no toxicity. This confirms previous safety data and validates translation of systemic gene delivery for dysferlinopathy patients.

Citing Articles

Plasma membrane repair defect in Alzheimer's disease neurons is driven by the reduced dysferlin expression.

Bulgart H, Lopez Perez M, Tucker A, Giarrano G, Banford K, Miller O FASEB J. 2024; 38(20):e70099.

PMID: 39400395 PMC: 11486262. DOI: 10.1096/fj.202401731RR.

Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and Therapeutic Possibilities.

Poudel B, Fletcher S, Wilton S, Aung-Htut M Int J Mol Sci. 2024; 25(11).

PMID: 38891760 PMC: 11171558. DOI: 10.3390/ijms25115572.

The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments.

Anwar S, Yokota T Biomolecules. 2024; 14(3).

PMID: 38540676 PMC: 10968265. DOI: 10.3390/biom14030256.

Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study.

Doody A, Alfano L, Diaz-Manera J, Lowes L, Mozaffar T, Mathews K BMC Neurol. 2024; 24(1):96.

PMID: 38491364 PMC: 10941356. DOI: 10.1186/s12883-024-03588-1.

Optimization strategies and advances in the research and development of AAV-based gene therapy to deliver large transgenes.

Kolesnik V, Nurtdinov R, Oloruntimehin E, Karabelsky A, Malogolovkin A Clin Transl Med. 2024; 14(3):e1607.

PMID: 38488469 PMC: 10941601. DOI: 10.1002/ctm2.1607.

References

Qu W, Wang M, Wu Y, Xu R . Scalable downstream strategies for purification of recombinant adeno- associated virus vectors in light of the properties. Curr Pharm Biotechnol. 2015; 16(8):684-95. PMC: 5388796. DOI: 10.2174/1389201016666150505122228. View

Barthelemy F, Wein N, Krahn M, Levy N, Bartoli M . Translational research and therapeutic perspectives in dysferlinopathies. Mol Med. 2011; 17(9-10):875-82. PMC: 3188867. DOI: 10.2119/molmed.2011.00084. View

Lostal W, Bartoli M, Bourg N, Roudaut C, Bentaib A, Miyake K . Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet. 2010; 19(10):1897-907. DOI: 10.1093/hmg/ddq065. View

Aoki M, Liu J, Richard I, Bashir R, Britton S, Keers S . Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. Neurology. 2001; 57(2):271-8. DOI: 10.1212/wnl.57.2.271. View

Emmerling V, Fischer S, Stiefel F, Holzmann K, Handrick R, Hesse F . Temperature-sensitive miR-483 is a conserved regulator of recombinant protein and viral vector production in mammalian cells. Biotechnol Bioeng. 2015; 113(4):830-41. DOI: 10.1002/bit.25853. View

Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C . Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet. 1998; 20(1):31-6. DOI: 10.1038/1682. View

Rodino-Klapac L, Janssen P, Montgomery C, Coley B, Chicoine L, Clark K . A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. J Transl Med. 2007; 5:45. PMC: 2082019. DOI: 10.1186/1479-5876-5-45. View

Grose W, Clark K, Griffin D, Malik V, Shontz K, Montgomery C . Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLoS One. 2012; 7(6):e39233. PMC: 3376115. DOI: 10.1371/journal.pone.0039233. View

Grieger J, Soltys S, Samulski R . Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector. Mol Ther. 2015; 24(2):287-297. PMC: 4817810. DOI: 10.1038/mt.2015.187. View

10.

Lennon N, Kho A, Bacskai B, Perlmutter S, Hyman B, Brown Jr R . Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem. 2003; 278(50):50466-73. DOI: 10.1074/jbc.M307247200. View

11.

Lostal W, Bartoli M, Roudaut C, Bourg N, Krahn M, Pryadkina M . Lack of correlation between outcomes of membrane repair assay and correction of dystrophic changes in experimental therapeutic strategy in dysferlinopathy. PLoS One. 2012; 7(5):e38036. PMC: 3362551. DOI: 10.1371/journal.pone.0038036. View

12.

Emmerling V, Fischer S, Kleemann M, Handrick R, Kochanek S, Otte K . miR-483 is a self-regulating microRNA and can activate its own expression via USF1 in HeLa cells. Int J Biochem Cell Biol. 2016; 80:81-86. DOI: 10.1016/j.biocel.2016.09.022. View

13.

Krahn M, Wein N, Bartoli M, Lostal W, Courrier S, Bourg-Alibert N . A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy. Sci Transl Med. 2010; 2(50):50ra69. DOI: 10.1126/scitranslmed.3000951. View

14.

Pozsgai E, Griffin D, Heller K, Mendell J, Rodino-Klapac L . Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice. Mol Ther. 2017; 25(4):855-869. PMC: 5383645. DOI: 10.1016/j.ymthe.2017.02.013. View

15.

Kerr J, Ward C, Bloch R . Dysferlin at transverse tubules regulates Ca(2+) homeostasis in skeletal muscle. Front Physiol. 2014; 5:89. PMC: 3944681. DOI: 10.3389/fphys.2014.00089. View

16.

Wang D, Zhong L, Nahid M, Gao G . The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv. 2014; 11(3):345-364. PMC: 4098646. DOI: 10.1517/17425247.2014.871258. View

17.

Ghosh A, Yue Y, Long C, Bostick B, Duan D . Efficient whole-body transduction with trans-splicing adeno-associated viral vectors. Mol Ther. 2007; 15(4):750-5. PMC: 2581720. DOI: 10.1038/sj.mt.6300081. View

18.

Lek A, Evesson F, Sutton R, North K, Cooper S . Ferlins: regulators of vesicle fusion for auditory neurotransmission, receptor trafficking and membrane repair. Traffic. 2011; 13(2):185-94. DOI: 10.1111/j.1600-0854.2011.01267.x. View

19.

Chicoine L, Rodino-Klapac L, Shao G, Xu R, Bremer W, Camboni M . Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogates. Mol Ther. 2013; 22(4):713-24. PMC: 3982494. DOI: 10.1038/mt.2013.246. View

20.

Emmerling V, Pegel A, Milian E, Venereo-Sanchez A, Kunz M, Wegele J . Rational plasmid design and bioprocess optimization to enhance recombinant adeno-associated virus (AAV) productivity in mammalian cells. Biotechnol J. 2015; 11(2):290-7. DOI: 10.1002/biot.201500176. View